Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.54 |
| ▸ | APBA1 | Q02410 | 2/20 | 0.54 |
| ▸ | CCR6 | P51684 | 1/20 | 0.54 |
| ▸ | P2RX7 | Q99572 | 18/20 | 0.51 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2013210 | 0.87 | ALDH1A1 (0.62) | ALDH1A1MAPTHPGDHTTCACNA1B | |
| SCHEMBL2005923 | 0.81 | ALDH1A1 (0.48) | ALDH1A1MAPTHPGDHTTCACNA1B | |
| SCHEMBL3287971 | 0.80 | P2RX7 (0.55) | P2RX7 | |
| SCHEMBL242375 | 0.78 | P2RX7 (0.54) | P2RX7 | |
| SCHEMBL1493397 | 0.77 | P2RX7 (0.52) | P2RX7 | |
| SCHEMBL242376 | 0.77 | P2RX7 (0.52) | P2RX7 | |
| SCHEMBL2008495 | 0.75 | ALDH1A1 (0.60) | ALDH1A1MAPTHPGDHTTCACNA1B | |
| SCHEMBL2005964 | 0.75 | ALDH1A1 (0.60) | ALDH1A1MAPTHPGDHTTCACNA1B | |
| SCHEMBL2009714 | 0.73 | ALDH1A1 (0.57) | ALDH1A1MAPTHPGDHTTCACNA1B | |
| SCHEMBL2005884 | 0.72 | KCNN4 (0.56) | ALDH1A1MAPTHPGDHTTCACNA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1937257-B1 | NOVEL ANTIBIOTICS COMPRISING BIS(1-ARYL-5-TETRAZ0LYL)METHANE DERIVATIVES | TNO (NL) | 2010-12-08 | — | — | EP | claimed |
| US-20080280964-A1 | Novel Antibiotics Comprising Bis(1-Aryl-5-Tetrazolyl)Methane Derivatives | NEDERLANDSE ORGANISATIE VOOR TOEGEPAST- NATUURWETENSCHAPPELIJK ONDERZOEK TNO (NL) | 2008-11-13 | — | — | US | claimed |
| US-7964625-B2 | Antibiotics comprising bis(1-aryl-5-tetrazoly1)methane derivatives | NEDERLANDSE ORGANISATIE VOOR TOEGEPAST-NATUURWETENSCHAPPELIJK ONDERZOEK TNO (NL) | 2011-06-21 | — | — | US | disclosed |
| EP-1937257-B1 | NOVEL ANTIBIOTICS COMPRISING BIS(1-ARYL-5-TETRAZ0LYL)METHANE DERIVATIVES | TNO (NL) | 2010-12-08 | — | — | EP | disclosed |
| US-20080280964-A1 | Novel Antibiotics Comprising Bis(1-Aryl-5-Tetrazolyl)Methane Derivatives | NEDERLANDSE ORGANISATIE VOOR TOEGEPAST- NATUURWETENSCHAPPELIJK ONDERZOEK TNO (NL) | 2008-11-13 | — | — | US | disclosed |
| EP-1769796-A1 | Novel antibiotics comprising bis(1-aryl-5-tetrazolyl)methane derivatives | Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO (NL) | 2007-04-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280964-A1 | Novel Antibiotics Comprising Bis(1-Aryl-5-Tetrazolyl)Methane Derivatives | LAS1L, AAAS, RPS5 | ALDH1A1 3743/4885MAPT 1629/4885HPGD 4361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.